Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 2.64 NOK
Change Today +0.18 / 7.32%
Volume 2.5M
BIONOR On Other Exchanges
As of 10:25 AM 04/21/15 All times are local (Market data is delayed by at least 15 minutes).

bionor pharma asa (BIONOR) Snapshot

2.48 NOK
Previous Close
2.46 NOK
Day High
2.66 NOK
Day Low
2.46 NOK
52 Week High
05/22/14 - 3.44 NOK
52 Week Low
04/29/14 - 1.91 NOK
Market Cap
Average Volume 10 Days
-0.29 NOK
Shares Outstanding
Dividend Yield
Current Stock Chart for BIONOR PHARMA ASA (BIONOR)

Related News

No related news articles were found.

bionor pharma asa (BIONOR) Related Businessweek News

No Related Businessweek News Found

bionor pharma asa (BIONOR) Details

Bionor Pharma ASA, a biotechnology company, is engaged in developing peptide based vaccines against viral diseases, primarily human immunodeficiency virus (HIV). The company’s HIV vaccine candidates in clinical development include Vacc-4x for reducing viral load and killing virus producing cells; and Vacc-C5 is indicated for the formation of antibodies against HIV in humans. The company is also developing Vacc-HIV, a preclinical phase vaccine, using the combination of Vacc-4x and Vacc-C5 vaccines; and Vacc-Flu, a preclinical phase influenza vaccine. In addition, it is developing vaccines for other viral diseases, including Hepatitis C, cytomegalovirus infection, and human papillomavirus infection. Further, the company provides nutraceutical products, such as Nutri5 and NutriPro. It operates in Norway and Europe, including Russia. The company was formerly known as Nutri Pharma ASA and changed its name to Bionor Pharma ASA in June 2010. Bionor Pharma ASA was founded in 1993 and is based in Oslo, Norway.

10 Employees
Last Reported Date: 04/13/15
Founded in 1993

bionor pharma asa (BIONOR) Top Compensated Officers

Executive Vice President
Total Annual Compensation: 1.9M NOK
Compensation as of Fiscal Year 2013.

bionor pharma asa (BIONOR) Key Developments

Bionor Pharma ASA Proposes Amendment to the Articles of Association

Bionor Pharma ASA announced that at the annual general meeting to be held on May 13, 215, will the propose amendment to the articles of association.

Bionor Pharma ASA Reports Consolidated and Parent Earnings Results for the Year Ended December 31, 2014

Bionor Pharma ASA reported consolidated and parent earnings results for the year ended December 31, 2014. On consolidated basis, revenues were NOK 1,766,000 against NOK 4,200,000 last year. LBITDA was NOK 58.3 million against NOK 75.8 million last year. Loss before tax, loss after tax and net loss was NOK 68,054,000 or NOK 0.29 per basic and diluted share against NOK 85,434,000 or NOK 0.42 per basic and diluted share, last year. Net cash used in operations was NOK 64,467,000 against NOK 68,566,000, last year. On parent basis, revenues were NOK 46,798,000 against NOK 31, 012,000, last year. Operating loss was NOK 14,541,000 against NOK 22,615,000, last year. Loss before tax and net loss was NOK 2,746,000 against NOK 6,572,000, last year. Loss attributable to equity holders of the parent was NOK 2,746,000 or NOK 0.01 per share against NOK 6,572,000 or NOK 0.03 per share last year. Net cash used in operations was NOK 62,862,000 against NOK 45,059,000, last year. Loss from continued operations was NOK 2,746,000 against NOK 6,572,000, last year.

Bionor Pharma ASA Announces Additions to the Executive Management Team and Interim CFO

Bionor Pharma ASA announced new members of the executive management team joining CEO, Dr. David Horn Solomon. The new members of the Company's executive management are all seasoned executives with prior experience from listed healthcare companies. Joining the team are: Dr. Barbara Ruskin joins Bionor on April 1, 2015. Dr. Ruskin has acted for over two decades advising diverse clients in the biotechnology and pharmaceutical industries.  She has broad expertise in worldwide patent portfolio management, litigation strategies, corporate transactions and due diligence on behalf of companies and investors. In addition to serving as Chief Patent Officer, Barbara will oversee all legal affairs for Bionor. Dr. Kamilla Rolsted joins Bionor on April 1, 2015. Dr. Rolsted has more than 15 years of experience from academia and the pharmaceutical industry, and has held various scientific and managerial positions. Most recently at Zealand Pharma, where Kamilla served as Director, heading Strategy and Planning. Kamilla will be responsible for strategy and business development at Bionor. Søren Keller has extensive experience as head of operations in both public and private research intensive organizations. Prior to joining Bionor, Søren served as director and general counsel to the management at Zealand Pharma A/S.  Søren will be responsible for all operations at Bionor. Additionally, Søren will serve as Interim CFO until the search for a permanent CFO is completed.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIONOR:NO 2.64 NOK +0.18

BIONOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIONOR.
View Industry Companies

Industry Analysis


Industry Average

Valuation BIONOR Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 256.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIONOR PHARMA ASA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at